Aditya Birla Sun Life Mutual Fund bought 2,61,420 shares of Emcure Pharmaceuticals for ₹47.50 Cr at ₹1817.00 apiece in a block deal.
A global pharmaceutical manufacturer established in 1981, Emcure Pharmaceuticals produces and markets a comprehensive range of drug formulations across multiple therapeutic areas for domestic and international markets. The company operates manufacturing facilities that serve patients globally, focusing on both generic and specialty pharmaceutical products. Emcure's diversified operations and geographic presence establish it as a significant player in the pharmaceutical industry.
Joint venture between Aditya Birla Capital and Sun Life Financial of Canada. Among India's top five AMCs with over Rs 6.5 lakh crore in AUM across 100+ schemes. MD and CEO A. Balasubramanian is one of the most outspoken fund industry voices in India. CIO Mahesh Patil oversees the equity book with a consistent large and multicap tilt.
